Literature DB >> 19411818

Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

C Erem1, I Nuhoglu, M Yilmaz, M Kocak, A Demirel, O Ucuncu, H Onder Ersoz.   

Abstract

BACKGROUND AND OBJECTIVES: Cushing's syndrome (CS) is associated with an increased cardiovascular mortality and morbidity. Chronic endogenous and exogenous hypercortisolism frequently induce a hypercoagulable and thrombotic condition. Little is known about hemostatic features of patients with CS. To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between cortisol and these hemostatic parameters and serum lipid profile in patients with CS. DESIGN AND METHODS: Twenty-four patients with CS and 24 age-matched healthy controls were included in the study. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factors V, VII, VIII, IX, and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor-1 (PAI-1), TFPI and TAFI, as well as common lipid variables, were measured. The relationships between serum cortisol and these hemostatic parameters were examined.
RESULTS: Compared with the control subjects, platelet count, PT, fibrinogen, AT-III and PAI-1 were significantly increased in patients with CS (p<0.05, p<0.0001, p<0.01, p<0.05, and p<0.0001, respectively), whereas aPTT and TFPI levels were significantly decreased (p<0.0001 and p<0.01, respectively). Plasma TAFI Ag levels did not significantly change in patients with CS compared with the controls. In patients with CS, we showed a negative correlation between serum cortisol: 08:00 h and aPTT (r:-0.469, p<0.05). Serum cortisol: 24:00 h was positively correlated with PAI-1 Ag levels (r: 0.479, p<0.05). INTERPRETATION AND
CONCLUSIONS: In conclusion, we found some important differences in the hemostatic parameters between the patients with CS and healthy controls. Increased platelet count, fibrinogen, PAI-1, and decreased TFPI levels in these patients represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess of mortality due to cardiovascular disease seen in patients with CS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411818     DOI: 10.1007/bf03345709

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  44 in total

1.  High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.

Authors:  F W G Leebeek; M P J Goor; A H C Guimaraes; G-J Brouwers; M P M Maat; D W J Dippel; D C Rijken
Journal:  J Thromb Haemost       Date:  2005-07-08       Impact factor: 5.824

2.  Biochemical basis for the hypercoagulable state seen in Cushing syndrome; discussion 1006-7.

Authors:  R C Jacoby; J T Owings; T Ortega; R Gosselin; E C Feldman
Journal:  Arch Surg       Date:  2001-09

3.  Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.

Authors:  G M Harris; C L Stendt; B J Vollenhoven; T E Gan; P G Tipping
Journal:  Am J Hematol       Date:  1999-03       Impact factor: 10.047

4.  Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Authors:  Marco Boscaro; Nicoletta Sonino; Alessandro Scarda; Luisa Barzon; Francesco Fallo; Maria T Sartori; Giovanni M Patrassi; Antonio Girolami
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

Review 5.  Assessment of hemostatic risk factors in predicting arterial thrombotic events.

Authors:  David Feinbloom; Kenneth A Bauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-08-11       Impact factor: 8.311

Review 6.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

7.  Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.

Authors:  Sabine Eichinger; Verena Schönauer; Ansgar Weltermann; Erich Minar; Christine Bialonczyk; Mirko Hirschl; Barbara Schneider; Peter Quehenberger; Paul A Kyrle
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

8.  Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients.

Authors:  T Abumiya; T Yamaguchi; T Terasaki; T Kokawa; K Kario; H Kato
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

9.  Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome.

Authors:  Merih Baykan; Cihangir Erem; Omer Gedikli; Arif Hacihasanoglu; Turan Erdogan; Mustafa Kocak; Ismet Durmuş; Levent Korkmaz; Sükrü Celik
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

10.  Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Authors:  L Bajzar; R Manuel; M E Nesheim
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  19 in total

1.  Immediate and delayed postoperative morbidity in functional and non-functioning pituitary adenomas.

Authors:  Anna Aulinas; Cristina Colom; Juan Ybarra; Fernando Muñoz; Pere Tresserras; Eugenia Resmini; Susan M Webb
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?

Authors:  Mattia Barbot; Viviana Daidone; Marialuisa Zilio; Nora Albiger; Linda Mazzai; Maria Teresa Sartori; Anna Chiara Frigo; Massimo Scanarini; Luca Denaro; Marco Boscaro; Sandra Casonato; Filippo Ceccato; Carla Scaroni
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

3.  Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

Authors:  Mattia Barbot; Valentina Guarnotta; Marialuisa Zilio; Filippo Ceccato; Alessandro Ciresi; Andrea Daniele; Giuseppe Pizzolanti; Elena Campello; Anna Chiara Frigo; Carla Giordano; Carla Scaroni
Journal:  Endocrine       Date:  2018-07-06       Impact factor: 3.633

4.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

5.  Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.

Authors:  Amit Tirosh; Maya Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2017-02-22       Impact factor: 2.936

Review 6.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

7.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

8.  Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?

Authors:  S Koutroumpi; L Spiezia; N Albiger; M Barbot; M Bon; S Maggiolo; S Gavasso; P Simioni; A Frigo; F Mantero; C Scaroni
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

9.  Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography.

Authors:  Nicola M Neary; O Julian Booker; Brent S Abel; Jatin R Matta; Nancy Muldoon; Ninet Sinaii; Roderic I Pettigrew; Lynnette K Nieman; Ahmed M Gharib
Journal:  J Clin Endocrinol Metab       Date:  2013-04-04       Impact factor: 5.958

10.  Pre-operative serum inflammation-based scores in patients with pituitary adenomas.

Authors:  Pedro Marques; Friso de Vries; Olaf M Dekkers; Wouter R van Furth; Márta Korbonits; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2020-11-24       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.